Hormonal
Cotadutide, a dual GLP-1 and glucagon receptor agonist, significantly reduces urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and chronic kidney disease compared to placebo, with effects sustained over 26 weeks.
If you have type 2 diabetes and early kidney disease, cotadutide (a daily injection) significantly reduces albumin in your urine, a key marker of kidney health. This effect is seen at higher doses (300-600 mg) and is sustained over time. It works on top of your current medications. While it causes some GI side effects, these are generally manageable and similar to other GLP-1 drugs. Discuss with your doctor if this dual-agonist approach is right for you, especially if you are not getting enough kidney protection from current treatments.
Cotadutide dose-dependently reduced UACR from baseline to the end of week 14, reaching significance at 300 mg (–43.9% [95% confidence interval L54.7 to L30.6]) and 600 mg (L49.9% [L59.3 to L38.4]) versus placebo; with effects sustained at week 26.
Why this rating
Phase 2b randomized controlled trial with 248 patients, double-blind, placebo-controlled, with statistical significance reported.
Source
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease
Viknesh Selvarajah et al. · Kidney International · 2024
DOI 10.1016/j.kint.2024.08.023
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →